cancer therapy

Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

by
Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more

The Evolution of Antibody-Drug Conjugates (ADCs): Opportunities and Challenges

by
The Evolution of Antibody-Drug Conjugates (ADCs): Opportunities and Challenges

At this year’s AACR annual meeting, there were hundreds of details related to ADC drugs. Leading ADC company Daiichi Sankyo announced the latest research progress of its HER3-targeted ADC product Patritumab deruxtecan (HER3-DXd); AstraZeneca also disclosed research updates on several drugs including AZD9592 (bispecific ADC) and AZD5335 (FRα ADC). Many Chinese pharmaceutical companies also showcased … Read more

Synergizing Catalysis with Post-catalysis Pseudo-Iron Release by Building Dynamic Catalytic Active Sites in Diatomic Nanozymes for Boosting Cancer Therapy

by
Synergizing Catalysis with Post-catalysis Pseudo-Iron Release by Building Dynamic Catalytic Active Sites in Diatomic Nanozymes for Boosting Cancer Therapy

Synergizing Catalysis with Post-catalysis Pseudo-Iron Release by Building Dynamic Catalytic Active Sites in Diatomic Nanozymes for Boosting Cancer TherapyJournal of the American Chemical Society ( IF 14.4 ) Pub Date : 2025-04-25DOI: 10.1021/jacs.5c03804Diatomic nanozymes have significant potential in tumor therapy, but their therapeutic efficacy is often limited by their low catalytic activity. Here, we propose … Read more

Degrader-Antibody Conjugates: Risks on the Path from Concept to Reality

by
Degrader-Antibody Conjugates: Risks on the Path from Concept to Reality

01 DAC‘s Emergence and Advantages Cancer therapeutics need to balance efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, and non-specific toxicity can lead to a low therapeutic index and side effects. The technology of Proteolysis-targeting chimeras (PROTACs), which achieve therapeutic effects by promoting the degradation of target proteins, is … Read more

A Journey into ADC Innovation

by
A Journey into ADC Innovation

After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more

In-Depth Analysis of ADCs: Part Two

by
In-Depth Analysis of ADCs: Part Two

Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more

ADC Technology: Innovations from Five Key Elements

by
ADC Technology: Innovations from Five Key Elements

History of ADC Drug Development Phase 1 (1906-1982), the concept of targeted therapy was proposed, and the technology took shape. Phase 2 (1983-2011), transition from clinical trials to commercialization, Mylotarg® was approved for market. Phase 3 (2012-present), explosive growth of ADC products. The five key elements of ADC drugs are target, antibody, linker, cytotoxic agent, … Read more

The Competitive Landscape Behind Coupling in Drug Development

by
The Competitive Landscape Behind Coupling in Drug Development

To improve the DMPK characteristics, many studies have explored the coupling of PROTAC payloads with monoclonal antibodies to create a new molecule known as “Antibody-Drug Conjugates (DAC).” This allows for more effective delivery of PROTAC degraders in vivo. ▲ Structure of DAC (Image Source: Reference 1) Compared to PROTAC molecules, DAC has several potential advantages: … Read more

Degrader-Antibody Conjugates: The Risky Path from Concept to Reality

by
Degrader-Antibody Conjugates: The Risky Path from Concept to Reality

The Emergence and Advantages of DAC Cancer therapeutics need to achieve a balance between efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, non-specific toxicity can lead to a low therapeutic index and side effects. The technology of proteolysis-targeting chimeras (PROTACs), which achieves therapeutic effects by promoting the degradation of … Read more

What Magic Do ADCs and RDCs Hold?

by
What Magic Do ADCs and RDCs Hold?

ADCs (Antibody-Drug Conjugates) and RDCs (Radionuclide Conjugates) are innovative drugs that have gained significant attention in recent years, demonstrating enormous potential in the field of oncology. They are referred to as the “magic bullets” of tumor-targeted therapy because they enable precise treatment while avoiding damage to normal cells. ADC drugs link antibodies with known effective … Read more